Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Revista de la OFIL
versión On-line ISSN 1699-714Xversión impresa ISSN 1131-9429
Resumen
CLARAMUNT-GARCIA, R; MUNOZ-CID, CL y SANCHEZ-RUIZ, A. Tumor lysis syndrome in hematologic patient. Rev. OFIL·ILAPHAR [online]. 2022, vol.32, n.4, pp.407-409. Epub 23-Oct-2023. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x20220004000017.
Tumor lysis syndrome (TLS) is a life-threatening complication characterized by a massive lysis of tumor cells. The following is the case of a 28-year-old man diagnosed with high-grade B-cell nonHodking lymphoma. The patient presented a TLS after the administration of chemotherapy. This case is of special interest due to the pharmaco logical recommendations proposed by the Pharmacy Service regarding the rasburicasa dose and the interactions at the electrolyte level with the concomitant medication prescribed during admission.
Palabras clave : Rasburicase; tumor lysis; lymphoma.